Clinical TrialsSearch results
Number of results: 238
Other
- Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults (JALSG ALL202-O)
- Acute lymphoblastic leukemia
- Japan Adult Leukemia Study Group
- 2005-08-17
Recruiting
- Effect of single-drug treatment on acute low-tone sensorineural hearing loss
- acute low-tone sensorineural hearing loss
- Ministry of Health, Labour and Welfare
- 2009-08-15
Other
- Phase II study of cord blood transplantation using myeloablative conditioning in adult patiants (C-SHOT 0603)
- Acute leukemia, Chronic myelogenous leukemia, Myelodysplastic syndrome
- Research Grant on Tissue Engineering from the Japanese Ministry of Health, Labor & Welfare
- 2007-10-29
Other
- Phase III clinical trial for AT-877 (i.v.) in patients with acute ischemic stroke. Placebo-controlled, double-blind add-on therapy to antiplatelet drugs
- Acute ischemic stroke (excluding cardioembolic stroke)
- Asahi Kasei Pharma Corporation
- 2007-07-02
Other
- Efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma: a multicenter randomized controlled trial
- A primary hepatocellular carcinoma case with tumor foci numbering less than 3, each measuring 3 cm or less, Child-Pugh score of 7 or less, ages between 20 and 79 year, and indications for either surgical resection or radiofrequency ablation for the treatment
- Surgery vs. RFA (SURF) trial group
- 2009-04-01
Other
- Efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma: a prospective cohort study
- A case without informed consent for SURF-RCT among primary hepatocellular carcinoma cases with tumor foci numbering less than 3, each measuring 3 cm or less, Child-Pugh score of 7 or less, ages between 20 and 79 year, and indications for either surgical resection or radiofrequency ablation for the treatment
- Surgery vs. RFA (SURF) trial group
- 2009-04-01
Other
- Phase II trial of cetuximab plus irinotecan for FOLFOX and FOLFIRI-refractory patients with EGFR-positive advanced and/or metastatic colorectal cancer, evaluation of the safety and efficacy based on KRAS mutation status (T-CORE0801)
- 3rd line or later therapy for unresectable advanced and/or recurrent colorectal cancer
- NPO T-CORE (Tohoku Clinical Oncology Research and Education Society)
- 2009-01-31
Other
- Randomized pilot study comparing safety of irinotecan+S-1(IRIS)+bevacizumab and mFOLFIRI+bevacizumab for metastatic colorectal cancer (T-CORE0702)
- 1st line or 2nd line therapy for unresectable colorectal cancer
- NPO T-CORE (Tohoku Clinical Oncology Research and Education Society)
- 2007-07-22